^
Association details:
| Biomarker: | CD38 expression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers
Published date:
05/26/2022
Excerpt:
In the durvalumab arm, the gene expression of PSIP1 (HR 0.54 95%CI 0.31-0.94; p=0.029), PD-L1/CD274 (per 1 unit HR: 0.41 95%CI 0.21-0.77; p=0.006), CD38 (per 1 unit: HR 0.52 95%CI 0.29-0.92; p=0.026) as well as the GeparSixto immune signature (per 1 unit HR: 0.51 95%CI 0.27-0.97; p=0.041) were significant for improved DDFS, with a positive test for interaction with treatment arm for PD-L1/CD274 (interaction p=0.020). Our analysis suggests that biomarkers for immune response are linked to improved survival with neoadjuvant durvalumab therapy...
DOI:
10.1200/JCO.2022.40.16_suppl.583
